Arcturus Therapeutics Holdings (ARCT) Total Liabilities (2018 - 2026)

Arcturus Therapeutics Holdings' Total Liabilities history runs 9 years deep, the most recent figure standing at $54.0 million for Q1 2026.

• Quarterly Total Liabilities fell 44.86% year-over-year to $54.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.0 million (down 44.86% YoY) and the FY2025 annual result came in at $57.2 million, down 44.55% from the prior year.
• Total Liabilities was $54.0 million for Q1 2026 at Arcturus Therapeutics Holdings, down from $57.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $180.1 million in Q4 2022 and bottomed at $54.0 million in Q1 2026.
• A 5-year average of $124.1 million and a median of $141.6 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities climbed 22.02% — and 2025, when it slumped 46.88%.
• Arcturus Therapeutics Holdings' Total Liabilities stood at $180.1 million in 2022, then decreased by 16.21% to $150.9 million in 2023, then plunged by 31.68% to $103.1 million in 2024, then plunged by 44.55% to $57.2 million in 2025, then slipped by 5.45% to $54.0 million in 2026.
• Business Quant data shows ARCT's Total Liabilities at $54.0 million in Q1 2026, $57.2 million in Q4 2025, and $57.8 million in Q3 2025.